ASCO 2021 | New therapies for NSCLC
Heather A. Wakelee, MD, Stanford University, Stanford, CA, discusses salient advances in the treatment of non-small cell lung cancer (NSCLC). 2 novel therapies for NSCLC have recently received FDA approval, the KRAS G12C inhibitor sotarasib, which has a ~40% response rate in patients with metastatic KRAS G12C + NCSLC without mutation, and the bi-specific antibody amivantamab, which has been tested alone an in combination with EGFR TKI lazertinib for the treatment of EGFR mutated NSCLC, including but not limited to EGFR exon 20. In addition, several other antibody-drug conjugates and bi-specifics look promising in the EGFR and HER2 space. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Heather A. Wakelee, MD has received research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Merck, Novartis, Pharmacyclics, Sea Gen, Xcovery; is on the advisory board (compensated) of AstraZeneca, Xcovery, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn; is on the advisory board (not compensated) of Merck Genentech/Roche; the president elect at IASLC; part of the executive committee at ECOG-ACRIN.
